First clinical results of Microsure's MUSA published

Our clinical partner Maastricht University Medical Center (MUMC+) published their first-in-human trial using our robotic platform MUSA for treating breast cancer-related lymphedema.

One of the key advancements in reconstructive microsurgery is supermicrosurgery. Supermicrosurgery is limited by the precision and dexterity of the surgeon’s hands. Microsure’s MUSA helps to overcome these human limitations and its feasibility and safety has now been proven in patients with breast-cancer related lymphedema.

With Microsure’s MUSA it is feasible to connect vessels with a diameter as small as 0.3 mm for reconstruction of lymphatic flow and vascularized tissue transplantation. A prospective randomized pilot from MUMC+ compared robot-assisted and manual supermicrosurgical lymphatico-venous anastomosis (LVA) in treating breast cancer-related lymphedema.

Please click HERE to view the results of the clinical trial.